Preventive Care

Preventive care applies epidemiological and pathophysiological principles to interrupt disease processes before clinical manifestation, operating across three levels: primary prevention (averting disease onset), secondary prevention (detecting presymptomatic disease), and tertiary prevention (minimizing disability from established disease). Primary prevention targets modifiable risk factors and employs immunizations — vaccines stimulate adaptive immunity by presenting attenuated or inactivated antigens to antigen-presenting cells, which activate T-helper cells and B-lymphocytes to produce pathogen-specific antibodies and memory cells, providing long-term protection without causing disease. The CDC immunization schedule is guided by immunological principles: conjugate vaccines (PCV13, Hib) link polysaccharide antigens to protein carriers to elicit T-cell-dependent immune responses in infants whose immature immune systems cannot mount adequate responses to polysaccharides alone. Secondary prevention through screening follows principles established by Wilson and Jungner: the disease must have a detectable preclinical phase, an available and acceptable screening test, and an effective treatment that improves outcomes when applied early versus late. The NP applies the USPSTF grading system (A/B = recommended, C = offer selectively, D = recommend against, I = insufficient evidence) to guide evidence-based screening decisions. Cancer screening exploits the natural history of neoplastic progression — colorectal cancer screening via colonoscopy detects and removes adenomatous polyps before they complete the adenoma-carcinoma sequence (APC gene inactivation → KRAS mutation → p53 loss → carcinoma, typically evolving over 10-15 years). Cervical cancer screening (Pap smear/HPV co-testing) detects dysplasia caused by high-risk HPV oncoproteins E6 and E7, which inactivate tumor suppressors p53 and Rb respectively, before invasive carcinoma develops. Cardiovascular risk assessment uses the ACC/AHA Pooled Cohort Equations to estimate 10-year atherosclerotic cardiovascular disease (ASCVD) risk, integrating modifiable factors (total cholesterol, HDL, systolic blood pressure, smoking, diabetes) with non-modifiable factors (age, sex, race) — a 10-year risk ≥7.5% triggers statin therapy discussion because the net benefit of LDL reduction (through HMG-CoA reductase inhibition, which upregulates hepatic LDL receptors and reduces circulating atherogenic lipoproteins) exceeds the risk of adverse effects. Metabolic syndrome screening identifies the clustering of insulin resistance (fasting glucose ≥100 mg/dL), visceral adiposity (waist circumference >40 inches male, >35 inches female), dyslipidemia (triglycerides ≥150, HDL <40 male/<50 female), and hypertension (≥130/85) — this cluster reflects underlying adipocyte dysfunction with excessive free fatty acid release, chronic low-grade inflammation (elevated CRP, IL-6, TNF-alpha), and progressive pancreatic beta-cell exhaustion that culminates in type 2 diabetes if unaddressed.